A carregar cotações...

Previsão

O preço-alvo médio dos analistas é € 4,31 (+92,41%). A mediana é € 4,31 (+92,41%).

Comprar	6
Manter	3
Vender	0

Discussões na comunidade

Ainda não há nenhuma discussão sobre este ativo.

Iniciar discussão

Notícias Ir para o feed de notícias

Sensus Healthcare: shareholders re-elect directors and ratify auditor

At Sensus Healthcare’s annual meeting, Eric Sachetta and Michael J. Sardano were re-elected as Class II directors for three-year terms. Shareholders also voted, in a non-binding advisory vote, to approve executive compensation for 2025 and ratified Carr, Riggs & Ingram as the independent auditor for fiscal year 2026. Sensus reported weak Q1 results with EPS of -$0.16 and revenue of $3.4 million, while the stock is trading near its 52-week low. » Mais em de.investing.com
Sensus Healthcare misses Q1 forecasts after sharp revenue decline

Sensus Healthcare reported Q1 2026 EPS of -$0.16 and revenue of $3.4 million, both below analyst expectations. Revenue fell 59% year over year, weighed down by missed sales to its largest customer and a shift to new business models. Adjusted revenue growth on a comparable basis was +26%. Management sees potential in new specific CPT codes and the Sensus Link software platform to improve reimbursement and drive future revenue growth. » Mais em de.investing.com
Acquisition leads to change of auditor at Sensus Healthcare

Sensus Healthcare dismissed Berkowitz Pollack Brant Advisors + CPAs (BPB) and appointed Carr, Riggs & Ingram (CRI) as its new independent auditor after CRI acquired certain assets of BPB’s capital markets business (effective Jan. 1, 2026). BPB’s audit report for the fiscal year ended Dec. 31, 2024, contained no disclaimers, modifications or disagreements with Sensus. The company also reported that a previously disclosed material IT-related control weakness had been remediated as of Dec. 31, 2024. In addition, Sensus reported revenue that exceeded expectations in the third quarter of 2025 and several board and management personnel changes, including the appointment of Larry Biscotti to the board of directors and the promotion of Michael Sardano to chief commercial officer. » Mais em de.investing.com
Sensus Healthcare adds Eric Sachetta to board of directors

Sensus Healthcare has appointed Eric Sachetta to its board of directors; he replaces the late longtime member Bill McCall. Sachetta comes from Sachetta, LLC and brings experience in financial advisory, leadership and client service, as well as several professional qualifications. The micro‑cap company (about $69m) has recently seen a share-price rise but is struggling with profitability; for Q3/2025 Sensus beat revenue and earnings forecasts (revenue $6.9m, loss per share $0.06). » Mais em de.investing.com
Sensus Healthcare beats Q3 revenue forecast, stock rises in after-hours trading

Sensus Healthcare reported Q3 2025 revenue of $6.9 million, topping the forecast of $6.25 million. Earnings per share were -$0.06 versus an expected -$0.08, and the net loss was $0.9 million. Gross margin fell to 39.1%, while the cash position rose to $24.5 million. Management points to new reimbursement codes and international expansion (focus on Japan) as growth drivers; the stock increased 5.15% in after-hours trading. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, SENSUS HEALTHCARE DL-,01 Aktie registou receitas de € 2,01 mi e um ganho líquido de -€ 7,67 mi

(EUR)	junho de 2026	YoY
Receitas	2,01 mi	67,67%
Ganho bruto	673,81 mil	72,64%
Ganho líquido	-7,67 mi	771,32%
EBITDA	-2,66 mi	95,53%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 48,61 mi
Número de ações	16,46 mi
Máximo/mínimo de 52 semanas	€ 4,98 - € 2,41
Dividendos	Não
Beta	1,19
PER (PE Ratio)	-3,47
PEG (PEG Ratio)	0,03
P/VC (PB Ratio)	1,45
P/V (PS Ratio)	3,06

Perfil da empresa

A Sensus Healthcare, Inc., uma empresa de dispositivos médicos, fabrica e vende dispositivos de radioterapia a prestadores de cuidados de saúde em todo o mundo. A empresa utiliza a radioterapia superficial (SRT), uma tecnologia de raios X de baixa energia, no seu portefólio de dispositivos de tratamento. Oferece o SRT-100, um sistema de radioterapia superficial de baixa energia por raios X fotónicos que proporciona aos doentes uma alternativa à cirurgia para o tratamento de cancros da pele não melanoma, incluindo carcinomas basocelulares e espinocelulares, bem como outras afeções cutâneas, como queloides; e o SRT-100 Vision, que disponibiliza ao utilizador uma aplicação de planeamento de tratamento adaptada à SRT, que integra o módulo de imagiologia por ultrassons de alta frequência incorporado, a análise volumétrica de tumores, o planeamento das margens do feixe e os parâmetros de dosimetria. A empresa oferece também o SRT-100 Plus; o programa de serviço Sentinel, que oferece aos seus clientes proteção para os seus sistemas; e serviços de aluguer de lasers em consultório. Além disso, vende substitutos descartáveis de blindagem de chumbo e itens descartáveis de segurança contra radiação, como aventais e protetores oculares, película para sondas de ultrassons e pontas aplicadoras descartáveis para tratar lesões de vários tamanhos e diversas zonas do corpo. A Sensus Healthcare, Inc. foi constituída em 2010 e tem sede em Boca Raton, Florida.

Nome	SENSUS HEALTHCARE DL-,01 Aktie
CEO	Joseph C. Sardano
Sede	Boca Raton, fl EUA
Site	sensushealthcare.com
Setor	Bens de consumo não essenciais
Indústria	Bens de consumo duradouros
Entrada em bolsa	26/07/2016
Colaboradores	60